抗VEGF药物辅助治疗新生血管性青光眼  

Adjuvant treatment of neovascular glaucoma with anti-VEGF

作　　者：师留坤 杨瑾[1] 

机构地区：[1]天津医科大学眼科临床学院 天津市眼科医院 天津市眼科学与视觉科学重点实验室 天津市眼科研究所,300000

出　　处：《国际眼科纵览》2015年第6期376-381,共6页International Review of Ophthalmology

摘　　要：新生血管性青光眼（neovascular glaucoma,NVG）为眼内缺血性疾病造成的严重并发症.由于缺血产生高浓度的血管内皮生长因子（vascular endothelial growth factor,VEGF）,在前房中导致虹膜新生血管的形成并持续存在,引起房水排出受阻.抗VEGF药物可与VEGF受体结合,使VEGF失活,从而延迟虹膜新生血管的形成.抗VEGF药物（贝伐单抗、雷珠单抗等）经前房或玻璃体腔注射联合传统治疗手段如小梁切除术、青光眼减压阀植入术、玻璃体切除术、全视网膜光凝术等可治疗NVG.Neovascular glaucoma （NVG） is a severe complication of ocular ischemia diseases.High concentration of vascular endothelial growth factor （VEGF） exists in anterior segment which leads to iris neovascularization.Aqueous humor outflow will be blocked.Anti-VEGF agent can combine with VEGF receptor and block VEGF, and to a certain extent delay the appearance of iris neovascularization.Intravitreal or intracameral injection of anti-VEGF agents （such as bevacizumab, ranibizumab and so on） combined with the traditional treatment such as trabecutectomy, glaucoma valve implantation, vitrectomy, panretinal photocoagulation are good choices to treat neovascular glaucoma.

关 键 词：新生血管性青光眼 血管内皮生长因子 贝伐单抗 雷珠单抗 

分 类 号：R775[医药卫生—眼科]